2‐Hydroxy‐4‐benzyloxylimine Resveratrol Derivatives as Potential Multifunctional Agents for the Treatment of Parkinson's Disease

• DOI: 10.1002/cmdc.202200629
• Publication Date: 2023-01-09T18:18:57Z
• Authors: Zhongcheng Cao; Tianlong Zhang; Xianwu Fu; Xingyue Wang; Qian Xia; Lei Zhong; Jiang Zhu
• Keywords: Trolox; MPTP

Abstract A series of 2‐hydroxy‐4‐benzyloxylimine resveratrol derivatives was designed, synthesized and evaluated as multifunctional agents for the treatment Parkinson's disease. The results revealed that most possessed good activities. Among them, representative compound ( E )‐5‐[(4‐fluorobenzyl)oxy]‐2‐{[(4‐hydroxyphenyl)imino]methyl}phenol 7 h ) exhibited excellent MAO‐B inhibition (IC 50 =8.43×10 −3 μM) high antioxidant activity (ORAC=3.45 Trolox equivalent). Additionally, displayed metal chelating ability, appropriate blood–brain barrier (BBB) permeability, significant neuroprotective effect, great anti‐neuroinflammatory activity. Furthermore, can also ameliorate 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced disease symptoms in mice. Therefore, found to be a promising candidate further development against PD.